Medicus Pharma Ltd. (MDCX)
| Market Cap | 3.80M -91.9% |
| Revenue (ttm) | n/a |
| Net Income | -56.66M |
| EPS | -82.98 |
| Shares Out | 1.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,697 |
| Open | 3.090 |
| Previous Close | 3.120 |
| Day's Range | 3.000 - 3.180 |
| 52-Week Range | 2.921 - 139.000 |
| Beta | -0.30 |
| Analysts | Strong Buy |
| Price Target | 225.00 (+7,375.08%) |
| Est. Earnings | Nov 13, 2026 |
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was inco... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MDCX stock is "Strong Buy." The 12-month stock price target is $225.0, which is an increase of 7,375.08% from the latest price.
News
Medicus Pharma Ltd trading halted, news pending
19:50 EDT Medicus Pharma (MDCX) Ltd trading halted, news pending
Medicus Pharma cites about $90M raised to advance CD228V, SkinJect, Teverelix
Medicus Pharma (MDCX) announced a shareholder update celebrating its third anniversary, saying approximately $90M raised through equity and debt financing over three years supported clinical developme...
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potent...
Medicus Pharma submits optimized Teverelix registrational protocol to FDA
Medicus Pharma (MDCX) announced that it has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration, FDA, for Teverelix, its investigational, n...
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy Pro...
Medicus to focus future clinical development of SkinJect on Gorlin syndrome
Medicus Pharma (MDCX) announced that it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and c...
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.
Medicus Pharma price target raised to $1 from 90c at Alliance Global
Alliance Global analyst Matthew Venezia raised the firm’s price target on Medicus Pharma (MDCX) to $1 from 90c and keeps a Buy rating on the shares following a transfer of…
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussi...
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications Company prioritizes CD228V precision oncolo...
Medicus Pharma price target lowered to 90c from $1 at Alliance Global
Alliance Global analyst Scott Henry lowered the firm’s price target on Medicus Pharma (MDCX) to 90c from $1 and keeps a Buy rating on the shares post tithe Q2 report.
Medicus Pharma reports Q2 EPS (21c) vs (43c) last year
“The second quarter of 2026 marked a defining period for Medicus as we successfully advanced both of our lead therapeutic platforms into their next stages of clinical and regulatory development,…
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Ex...
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operat...
Medicus Pharma Teverelix granted investigational new drug authorization in UAE
Medicus Pharma (MDCX) announced that the United Arab Emirates, or UAE, Department of Health – Abu Dhabi has granted investigational new drug authorization for the company’s PRECISION-E2 Phase 2a clini...
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health Randomized Phase 2a PRECISION-E2 study designed to evaluate a...
Medicus Pharma initiated with a Buy at Alliance Global
Alliance Global initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $1 price target Medicus is a life sciences company focused on the clinical development of novel therapeutic…
Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study
Medicus Pharma (MDCX) announced the FDA has completed its safety review of the company’s Investigational New Drug application for SKNJCT-005 and issued a “Study May Proceed” letter authorizing the ini...
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended pati...
Medicus Pharma receives FDA feedback, IRB approval for Teverelix study
Medicus Pharma (MDCX) announced that it has received written feedback from the FDA and central Institutional Review Board, or IRB, approval, with modifications, for its optimized Phase 2 clinical stud...
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan Regulatory and ethical-r...
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Company's presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the ...
Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA
Medicus Pharma (MDCX) announced the submission of a Rare Pediatric Disease Designation request to the FDA for SkinJect, the company’s investigational doxorubicin-containing microneedle array patch, fo...
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs ...
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine...